Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17613216 | GENE EDITING IN DIVERSE BACTERIA | Non-Final OA | President and Fellows of Harvard College |
| 16984885 | COMPOSITIONS AND METHODS FOR IDENTIFYING A SINGLE-NUCLEOTIDE VARIANT | Final Rejection | President and Fellows of Harvard College |
| 16616655 | ALTERED GUIDE RNAS FOR MODULATING CAS9 ACTIVITY AND METHODS OF USE | Non-Final OA | North Carolina State University |
| 18490880 | TRANSCRIPTIONAL PROGRAMMING IN A BACTEROIDES CONSORTIUM | Non-Final OA | Georgia Tech Research Corporation |
| 18256768 | HYDROGEN PEROXIDE EVOLVED HOST CELL | Non-Final OA | MedImmune Limited |
| 17552431 | ENGINEERED SSDNASE-FREE CRISPR ENDONUCLEASES | Non-Final OA | MONSANTO TECHNOLOGY LLC |
| 18969910 | Programmable Cleavage of RNA | Non-Final OA | New England Biolabs, Inc. |
| 17636750 | COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION | Final Rejection | Duke University |
| 18278255 | DNA APTAMERS AND COMPOSITIONS TARGETING ALPHA-SYNUCLEIN AND METHODS OF MAKING AND USING SAME | Non-Final OA | Qatar Foundation for Education, Science and Community Development |
| 17162053 | COMPOSITIONS, SYSTEMS, AND METHODS FOR BASE DIVERSIFICATION | Non-Final OA | Pairwise Plants Services, Inc. |
| 17084721 | TYPE V CRISPR-CAS BASE EDITORS AND METHODS OF USE THEREOF | Non-Final OA | Pairwise Plants Services, Inc. |
| 18495741 | SUGAR-CONJUGATED LIPID NANOPARTICLES AND METHODS OF USE THEREFOR | Non-Final OA | University of Virginia Patent Foundation |
| 18753324 | NOVEL TYPE OF CRISPR/CAS SYSTEM | Non-Final OA | SNIPR BIOME APS |
| 18734772 | COMPOSITIONS AND METHODS FOR RNA SYNTHESIS | Non-Final OA | LineaRx, Inc. |
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | Final Rejection | Intellia Therapeutics, Inc. |
| 17430669 | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE | Non-Final OA | BEAM THERAPEUTICS INC. |
| 17430289 | SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE | Final Rejection | BEAM THERAPEUTICS INC. |
| 18455209 | METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS | Non-Final OA | EARLI Inc. |
| 18021450 | CONSTITUTIVELY ACTIVE TCF1 TO PROMOTE MEMORY-ASSOCIATED TRAITS IN CAR T CELLS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18011311 | METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS | Final Rejection | Horizon Discovery Limited |
| 18265603 | NUCLEIC ACID MOLECULE FOR INDUCTION OF ASYMMETRIC RNAI FOR INHIBITING EXPRESSION OF ROR-BETA | Non-Final OA | Olix Pharmaceuticals, Inc. |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 16963809 | COMPOSITIONS AND METHODS FOR REGULATING A BIOLOGICAL PROCESS | Non-Final OA | The University of Memphis Research Foundation |
| 18027723 | COMPOSITIONS AND METHODS FOR ENHANCED NUCLEIC ACID TARGETING SPECIFICITY | Non-Final OA | Acrigen Biosciences, Inc. |
| 18149913 | CONSTRUCTS, COMPOSITIONS, CELLS AND METHODS FOR INCREASED RECOMBINANT PROTEIN EXPRESSION BY TARGETED INTEGRATION AND AMPLIFICATION | Non-Final OA | INPAMAC BIOTECH CANADA INC. |
| 18085121 | APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT | Non-Final OA | Shanghai Tolo Biotechnology Company Limited |
| 18053696 | METABOLIC ENGINEERING OF CUPRIAVIDUS NECATOR FOR IMPROVED FORMATE UTILIZATION | Non-Final OA | Alliance for Energy Innovation, LLC |
| 17922058 | METHODS FOR REDUCING RNA IMMUNOGENICITY AND RNA MOLECULES WITH DECREASED IMMUNOGENICITY | Non-Final OA | RiboPro B.V. |
| 17518209 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING AND TRANSLATION | Non-Final OA | Stoke Therapeutics, Inc. |
| 17267947 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT | Final Rejection | Aspira Women's Health Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy